Aura Biosciences to Participate in Upcoming Investor Conference
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference:
Covered in this story
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.